Company Encyclopedia
View More
name
YD Bio
YDES.US
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.
1.876 T
YDES.USMarket value -Rank by Market Cap -/-

Financial Score

14/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking112/389
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-42.69%E
    • Profit Margin-276.58%E
    • Gross Margin30.44%C
  • Growth ScoreB
    • Revenue YoY45.76%A
    • Net Profit YoY-10509.73%E
    • Total Assets YoY2036.98%A
    • Net Assets YoY28560.72%A
  • Cash ScoreB
    • Cash Flow Margin-36.16%D
    • OCF YoY45.76%A
  • Operating ScoreE
    • Turnover0.14E
  • Debt ScoreA
    • Gearing Ratio3.99%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES | YDES Stock News

    YD Bio Limited celebrated its public listing on the Nasdaq Global Market under the ticker YDES by ringing the Opening Bell at Nasdaq MarketSite in New York. This milestone enhances the company's capital base and global profile, facilitating the commercialization of its cancer detection and regenerative medicine technologies. CEO Dr. Ethan Shen highlighted the strategic partnerships and licenses that position YD Bio for growth in the U.S. capital markets, aiming to advance R&D and launch pipeline products to improve patient outcomes.

    StockTitan·
    US
    YDES
    +27.27%
    StockTitan·
    US
    YDES
    +27.27%

    YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities | YDES Stock News

    YD Bio Limited's partner, EG Biomed US Inc., has achieved CAP accreditation for its laboratory in Bothell, Washington, enhancing its capabilities in cancer detection. This accreditation, recognized as a gold standard in laboratory quality, supports YD Bio's mission to improve patient outcomes through innovative diagnostics. Dr. Ethan Shen, CEO of YD Bio, emphasized the importance of this achievement in delivering reliable diagnostics. Additionally, EG Biomed presented new research on a biomarker for monitoring advanced pancreatic cancer at a recent conference, further establishing its scientific leadership.

    StockTitan·
    US
    YDES
    +27.27%
    StockTitan·
    US
    YDES
    +27.27%

    YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

    YD Bio Ltd :YD BIO LIMITED REPORTS UNAUDITED HALF YEAR 2025 FINANCIAL RESULTS

    Reuters·
    US
    YDES
    +27.27%
    Reuters·
    US
    YDES
    +27.27%

    YD Bio Limited Reports 9% Decline in Net Revenue to $204,007 for H1 2025

    YD Bio Limited reported a 9% decline in net revenue to $204.0 million for H1 2025, down from $225.0 million in the prior year. The decrease was attributed to a change in product mix, with the top five products generating 56% of total revenue. Operating expenses rose significantly to $2.0 million, leading to a net loss of $1.9 million. Cash reserves fell to $469,520 due to increased administrative and R&D costs. The company is advancing ocular therapies and expanding into oncology diagnostics.

    Reuters·
    US
    YDES
    +27.27%
    Reuters·
    US
    YDES
    +27.27%

    U.S. stock market midday update: YD Bio up 13.13%

    YD Bio rose 13.13%; Merus rose 36.30%, with a transaction volume of USD 2.527 billion; Fortis Pharmaceuticals rose 2.44%, with a transaction volume of USD 389 million; MoonLake Immunotherapeutics fell 89.35%, with a transaction volume of USD 379 million; AbbVie rose 0.06%, with a market capitalization of USD 390 billion

    Tracking Unusual Activity·
    US
    YDES
    +27.27%
    Tracking Unusual Activity·
    US
    YDES
    +27.27%